Fig. 1

miR-451a expresses poorly in serum of patients with BCa and its promoter is methylated in BCa cells. a, the volcanic map of 114 upregulated miRNAs and 195 downregulated miRNAs in serum of 12 BCa patients and 10 healthy controls in GSE113486 dataset; b, the heatmap of the top 50 differentially expressed miRNAs; c, serum expression of miR-451a in 392 BCa patients and 100 healthy controls in GSE113486 dataset; d, the relationship between miR-451a and survival of patients predicted by the KM-plotter website; e, miR-451a expression in BCa cell lines T24, 5637, TCCSUP, UM-UC3 and SV-HUC-1 cells determined by RT-qPCR; f, miR-451a chromosomal mapping and CpG island prediction; g, miR-451a expression in T24 and 5637 cells delivered with 5-aza-dC; h, promoter methylation in T24 cells (the top 3 haplotypes of high frequency were presented); i, promoter methylation in 5637 cells (the top 3 haplotypes of high frequency were presented). Data are represented as the means ± SD from three independent assays. Statistically significant differences were calculated using unpaired t-test (panel c), one-way (panel e) or two-way ANOVA (panel g), followed by Tukey’s multiple comparison test. **p < 0.01 vs DMSO treatment, ***p < 0.001 vs SV-HUC-1 cells or non-carcinoma